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Background: Cytomegalovirus infection and disease are 
potential risk factors for acute allograft rejection in renal 
transplant recipients. 
Methods: From October 1994 to July 1997, 477 con- 
secutive renal allograft recipients (397 first transplants 
and 80 retransplants) were included in the study. 
Cytomegalovirus infection (cytomegalovirus pp65 
antigen in leukocytes) and disease (infection and clinical 
symptoms or signs of disease) were examined pro- 
spectively for 3 months. No cytomegalovirus prophylaxis 
was given, and cytomegalovirus disease was treated 
with i.v. ganciclovir. The retransplantation of 4 patients 
transplanted twice during the study and 22 patients 
receiving kidneys from HLA-identical siblings were 
excluded from statistical analysis. Rejections were 
evaluated clinically (277 (61%)) and 173 (38%) also had 
a biopsy verified rejection. 
Results: Cytomegalovirus infection occurred in 64% of 
the patients and 24% experienced cytomegalovirus 
disease. In a multiple time-dependent Cox analysis 
independent significant predictors for clinical acute 
rejections were cytomegalovirus infection, RR=1.6 
(1.1-2.5, p=O.O2), cytomegalovirus disease, RR=2.5 
(1.2-5.l,p=O.O1). Among 173 patients with biopsy veri- 
fied rejection 72% of the patients had tubulointerstitial 
rejection whereas 28% had a vascular rejection. 
cytomegalovirus disease, but not cytomegalovirus in- 
fection was a predictor of tubulointerstitial rejection, 
RR=3.1 (l.l-9.3,p=O.O4). 
Conclusion: Cytomegalovirus infection and disease are 
independent risk factors for clinically acute rejection 
in kidney risk factor for biopsy verified acute tubulo- 
interstitial rejection in kidney allograft recipients. 
Use of intravenous immunoglobulin (IVIg) in addition 
to antiviral therapy for the treatment of CMV disease 
in heart transplanted patients with secondary 
hypogammaglobulinemia 
P MuAoz,l J Bermejo, E. Sarmiento, J. Palomo,2 
J. YaAez,* E. Fernandez-Cruz and J. Carbone 
Clinical Immunology Unit, ‘Microbiology Department 
and *Cardiology Department, University Hospital 
Gregorio Maranon. Madrid, Spain 
Introduction: Cytomegalovirus (CMV) disease occurs 
frequently after solid organ transplantation and has 
been associated with decreased patient and allograft 
survival. IVIg have been used in organ transplantation 
in combination with antiviral agents to treat established 
CMV disease. However, only limited data in heart trans- 
planted patients with secondary hypogammaglobu- 
linemia exist. 
Patients and Methods: We assessed the overall pre- 
valence of significant hypogammaglobulinemia in the 
post-transplantation period after heart transplantation. 
We present data on 5 heart transplanted patients with 
recurrent CMV infection, four of whom developed 
gastrointestinal disease. One of the patients associated 
acute graft rejection. An immunologic evaluation 
showed hypogammaglobulinemia (mean IgG levels: 
323+40 mg/dl (n.v. 700-1600 mg/dl)) in all the patients. 
The mean absolute number of CD4+ T-cells and 
B lymphocyte counts were 429?233 and 67240 cells/ 
mm3, respectively. IVIg (Flebogamma@) 200-400 mg/kg 
every 21 days plus antiviral treatment with gancyclovir 
was administered to the patients. After treatment the 
patients were followed-up for a mean period of 12 
months. 
Results: IVIg treatment, in combination with antiviral 
therapy, proved able to control CMV disease. There was 
a favorable clinical response and the patients became 
free of gastrointestinal symptoms. Detection of CMV 
antigens was negative after treatment. 
Conclusions: Even if our survey was limited to only 
five cases, the results indicated that addition of IVIg to 
antiviral chemotherapy might improve outcome in heart 
transplanted patients with CMV disease and hypo- 
gammaglobulinaemia. 
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Objective: To assess if keeping a previously placed IC is 
associated with an increase in morbidity in patients 
undergoing APSCT. 
Methods: We reviewed all pts who underwent APSCT 
with an IC in place from 3/97 to l/02. We compared these 
pts with a control group (no IC in place) that was 
matched by disease, age, and sex. 
Results: 43 pts (IC group) were matched with 43 
controls (no IC). In both groups the age (mean 40 years 
old), the sex distribution (58% females), and the 
duration of neutropenia (mean 8 days) were the same. 
Underlying malignancies included multiple myeloma 
(14 and 12) lymphoma (22 and 24) leukemia (3 and 3) 
and others (4 and 4) in the IC and no IC groups, 
respectively. Antibacterial and antifungal prophylaxis 
were used in 18 and 23 pts in the IC group vs 10 and 17 
pts in the no IC group (P=NS). The IC were used in 20 
of 43 pts within the 60 days of transplantation The 
endpoints shown in the table were used as markers of 
morbidity: 
Abstracts of the 12th ISIIH 2S37 
, r  
Fever 37 
Bloodstream infections (BC+) 9 
Use of vancomycin (VAN)/ 231 
amphotericin B (AMB) 4 
Days on antibiotics, mean (*SD) 14 (+-9) 
No. of readmissions at D+60 9 
Death 2 
No IC 
fn=43) P 
35 0.77 
6 0.57 
181 0.391 
4 0.99 
12 (a5) 0.51 
4 0.09 
1 0.99 
Conclusion: Keeping a previously placed IC did not 
seem to increase morbidity in this population of APSCT 
recipients. 
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Aim: Identification in HSCT R of a high risk population 
to develop AGNB B, who may benefit from anti- 
microbial preemptive therapy. 
Material and methods: A retrospective study conducted 
from January 1997 to December 2001; 258 HSCT R were 
included from the beginning of chemotherapy until 
neutropenia was resolved. We studied 231 febrile 
episodes, excluding B due to other microorganisms : 35 
with and 196 without B, which were evaluated analyzing 
age, sex, underlying disease, type of HSCT, grade of oral 
and gastrointestinal(G1) mucositis, abdominal and/or 
anal clinical site of infection, ICU requirement, and 
procedure-related mortality(PRM). 
Results: The prevalence of B was 13.5% (35/258). We 
found significant differences in : grade of GI mucositis 
manifested by diarrhea ~100Oml/day: 13/35 vs. 37/196, 
p=O.O02, RR=2.14, IC95%=1.16-3.94; abdominal/anal 
clinical site: 12/35 vs. 12/196,p=O.OOl,RR=4.50, IC 95% 
2.58-7.84; ICU requirement: 14/35 vs. 291196, p=O.OOl, 
RR=2.91, IC95% =1.62-5.26. The presence of diarrhea 
2 lOOOml/day, predicted B due to AGNB with sensitivity 
(S)=37% and specificity(Sp)=81% with a positive pre- 
dictive value (PPV) =25 % and negative predictive value 
(NPV)=87%; the presence of abdominal/anal site pre- 
dictedB withS=34%,Sp=93%,PPV=46% andNPV= 
88%. 
VRE infections have become a significant cause of 
morbidity and mortality among pt undergoing OLT. 
However, it is not known if VRE colonization pre-OLT 
is associated with worse outcomes. All adult pt listed for 
OLT at the University of Michigan from 1100 to 3102 
were eligible for study. Underlying illness, antimicrobial 
use, hospital stay, severity of liver disease, and other 
clinical data were gathered; rectal swabs for VRE were 
done at 4-6 month intervals pre-OLT. VRE cultures 
were repeated prior to transplant and every 5 days 
during the post-OLT hospitalization. Intra-operative 
bile cultures for VRE were obtained at OLT. Pt were 
followed for 2 months post-OLT to assess outcomes. 
Among 360 pt in the study, 42 (12%) were colonized 
with VRE prior to OLT. Of these 42, 64% were men; 
hepatitis C was the most common underlying diagnosis 
(26 %), and 12% had received a prior OLT. Colonized 
pt spent a mean of 14?14 days in hospital and received 
a mean of 46+-68 days of antimicrobial therapy during 
the previous 6 months. Of the 42 colonized pt, 11 died 
prior to OLT, 16 remain on the waiting list, 15 underwent 
OLT. Among these 15, 3 developed VRE-related 
infections post-OLT and 2 pt died, 1 secondary to VRE 
sepsis and endocarditis. 89 pt who were not colonized 
with VRE received an OLT; 9 (10%) died and 16 (18%) 
became colonized with VRE prior to discharge from 
hospital. Two of the 16 developed serious VRE-related 
infections that contributed to their deaths. 
VRE colonization is prevalent among pt awaiting 
OLT. Among 15 VRE colonized pt undergoing OLT, 3 
developed VRE-related infections; 2 of 16 pt who 
acquired VRE post-OLT developed VRE-related 
infections. VRE colonization prior to OLT does not 
appear to increase mortality. 
Comments: (1) The presence of diarrhea z lOOOml/day 
increased B risk by two times and was predictive in 1 of 
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5 episodes of fever with high NPV. (2) The presence of 
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of fever ( PPV 46%). (3) B due to AGNB increased ICU 
requirements nearly 3 times and doubled the risk of 
mortality-related procedure. 
Conclusion: We propose the use of empirical antibiotic 
preemptive therapy in neutropenic HSCT R with 
diarrhea 2 lOOOml/day or with abdominal/anal clinical 
site of infection, despite the presence of fever. 
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